Drug Profile
Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics
Alternative Names: Antibody therapeutics - Allinaire Therapeutics; Pulmonary diseases therapeutics - Allinaire TherapeuticsLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Indiana University School of Medicine
- Class Antibodies
- Mechanism of Action Immunomodulators; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in USA
- 28 Feb 2021 No recent reports of development identified for research development in Respiratory-tract-disorders in USA
- 12 Feb 2018 Allinaire Therapeutics receives SBTTR phase I grant from National Heart, Lung, and Blood Institute (NHLBI) for development of Respiratory tract disorders therapeutics